<DOC>
	<DOC>NCT00385580</DOC>
	<brief_summary>The purpose of this study is to learn if men with metastatic prostate cancer and rising Prostate Specific Antigen (PSA), who have been surgically castrated or are undergoing androgen deprivation with Luteinizing Hormone Releasing Hormone (LHRH) treatment, respond to dasatinib. The safety of this treatment will also be studied.</brief_summary>
	<brief_title>Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>males, 18 or older proven advanced prostate cancer documented metastatic disease rising PSA levels castrate levels of testosterone symptomatic CNS (brain or spinal cord) metastasis medical condition which may increase the risk of toxicity any prior or ongoing anticancer medical therapy or immunotherapy for prostate cancer other than primary androgen deprivation agents unable to take oral medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>